Saturday 17 October 2026
Export ACOG’s income statement to Excel — free account
Alpha Cognition Inc.
ACOG Healthcare Biotechnology
Alpha Cognition Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million. In the quarter to June 2026, revenue grew 267.6%, EPS grew 38.5% and free cash flow fell 109.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.19
0.26
−3.08%
Follow ACOG
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 11.24 | 11.04 | 10.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.87) | (16.64) | (10.13) | (22.92) | |
P/B ratio |
3.10 | 1.84 | 2.08 | 2.97 | |
Price to Tangible BV |
3.14 | 1.85 | 2.09 | 3.36 | |
EV/Sales |
0.00 | 4.87 | 6.11 | 7.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.48) | (2.44) | (2.20) | (3.78) | |
EV/FCF |
(4.42) | (2.40) | (2.18) | (3.15) | |
Quick Ratio |
5.61 | 7.70 | 10.67 | 7.32 | |
Current Ratio |
6.69 | 8.65 | 12.64 | 9.03 | |
Net Debt/EBITDA |
6.69 | 12.09 | 6.73 | 5.42 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.16 | 0.18 | 0.28 | |
Operating CF/Net income |
4.01 | 1.56 | 1.82 | 0.78 | |
Capex/Depreciation |
(5.95) | (5.42) | (0.04) | (57.97) | |
Interest Coverage |
14.06 | — | — | — | |
Research and Development Expense of Revenue |
20.19% | 17.46% | 31.02% | 32.97% | |
Selling, General and Administrative Expense of Revenue |
244.49% | 270.10% | 290.24% | 187.91% | |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.01 | 0.10 | |
Share Based Compensation of Revenue |
(47.69%) | 33.85% | 23.36% | 27.87% | |
Graham Net Nets |
0.32 | 0.54 | 0.48 | 0.30 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(21.04%) | (17.85%) | (24.23%) | (14.96%) | |
Free Cash Flow Yield |
(15.22%) | (18.03%) | (25.46%) | (23.59%) | |
Revenue per Share |
0.18 | 0.16 | 0.16 | 0.28 | |
Operating CF per Share |
(0.33) | (0.39) | (0.54) | (0.31) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.28) | |
Free Cash Flow per Share |
(0.33) | (0.40) | (0.54) | (0.59) | |
Cash per Share |
2.20 | 3.74 | 2.50 | 1.90 | |
Shareholders Equity per Share |
2.10 | 3.54 | 2.64 | 2.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.10 | 3.54 | 2.64 | 2.43 | |
Free Cash Flow |
(5.36) | (7.05) | (11.80) | (12.86) | |
Working Capital |
38.87 | 69.88 | 63.13 | 51.51 | |
Capital Expenditures |
(0.07) | (0.15) | 0.00 | (6.01) | |
Net Current Asset Value |
33.31 | 61.81 | 56.77 | 46.37 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.05 | 0.00 | 0.99 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.45 | 2.15 | 2.00 | 3.64 | |
Average Payables |
4.14 | 5.71 | 3.94 | 4.52 | |
Average Inventory |
— | 2.87 | 3.46 | 3.64 | |
Average Assets |
25.66 | 65.23 | 58.93 | 54.82 | |
Average Common Equity |
15.50 | 50.81 | 49.13 | 42.43 |
Columns are period end dates